Skip to main content
OpenTrials
Completed

NCT Number: NCT03500588

Vascular Endothelial Factor Gene Polymorphism in Preeclampsia

In this study, the investigators assessed one of the released protein factors during the pathophysiology of preeclampsia. They evaluated vascular endothelial growth factor gene mutation which affects the angiogenesis in case of inadequate placentation and its association with Doppler changes in the pulsatility index of the umbilical artery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Preeclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pre-Eclampsia Pregnancy Complications Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Beni-Suef University

Cairo, Beni Suweif Governorate, 12412, Egypt

About this study

Preeclampsia is a syndrome characterized by occurrence of hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves abnormalities in the development of placental vasculature early in pregnancy may result in relative placental under perfusion/hypoxia/ischemia, which then leads to release of factors into the maternal circulation that alter maternal endothelial function and cause hypertension and other manifestations of disease .Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Human VEGF gene is located on chromosome 6 and consists of 8 exons with alternate splicing, forming a family of proteins. There are several common single nucleotide polymorphisms (SNPs) in the VEGF gene, which could alter gene expression and protein production, and alter the risk of developing diseases characterized by deranged angiogenesis including preeclampsia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

More than 20 weeks gestation. Preeclamptic patients

Exclusion criteria

association with chronic disease (cardiac, hepatic, renal) and if the patient was known to have chronic hypertension.

association with auto-immune disease.

Treatment and study plan

PCR

Diagnostic Test

Polymerase chain reaction was used to diagnose gene polymorphism.

Doppler ultrasound

Device

Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .

Primary outcomes

  1. Correlation of VEGF gene mutation and preeclampsia

    Time frame: from 20 weeks until delivery

    Is VEGF gene polymorphism associated with preeclampsia

Secondary outcomes

  1. fetal and neonatal outcomes

    Time frame: from 20 weeks until first postpartum week.

    Intrauterine growth restriction

  2. maternal outcome

    Time frame: from 20 weeks until delivery

    Maternal admission to intensive care unit

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

Vascular Endothelial Growth Factor C/A 2578 Gene Polymorphism and Umbilical Artery Doppler in Preeclamptic Women

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Apr 18, 2018
Registry last updated
Mar 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.